



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy

This is the peer reviewed version of the following article:

Original

Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy / Pieroni, Marco; Machado, Diana; Azzali, Elisa; Santos Costa, Sofia; Couto, Isabel; Costantino, Gabriele; Viveiros, Miguel. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 58:15(2015), pp. 5842-5853. [10.1021/acs.jmedchem.5b00428]

Availability:

This version is available at: 11381/2822802 since: 2021-10-14T10:43:34Z

Publisher:

American Chemical Society

Published

DOI:10.1021/acs.jmedchem.5b00428

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

(Article begins on next page)

Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy

MARCO PIERONI, Diana Machado, Elisa Azzali, Sofia Santos Costa, Isabel Couto, Gabriele Costantino, and Miguel Viveiros

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.5b00428 • Publication Date (Web): 21 Jul 2015

Downloaded from <http://pubs.acs.org> on July 27, 2015

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Anti-TB Therapy

Marco Pieroni,^{†,#,} Diana Machado,^{§,#} Elisa Azzali,[†] Sofia Santos Costa,[§] Isabel Couto,[§]
Gabriele Costantino[†] and Miguel Viveiros^{§,*}*

[†]Dipartimento di Farmacia, P4T group, University of Parma, Parco Area delle Scienze 27/A,
Parma, 43124

[§]Grupo de Micobactérias, Unidade de Microbiologia Médica, Global Health and Tropical
Medicine (GHTM), Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa
(IHMT, UNL), Rua da Junqueira, 100, 1349-008 Lisbon, Portugal

KEYWORDS. Efflux pumps, Thioridazine, Tuberculosis, Antimicrobial Resistance, Medicinal
Chemistry.

Abstract

Tuberculosis, caused by *Mycobacterium tuberculosis*, is still one of the leading infectious diseases globally. Therefore, novel approaches are needed to face this disease. Efflux pumps are known to contribute to the emergence of *M. tuberculosis* drug resistance. Thioridazine has shown good anti-TB properties both *in vitro* and *in vivo*, likely due to its capacity to inhibit efflux mechanisms. Here we report the design and synthesis of a number of putative efflux inhibitors inspired by the structure of thioridazine. Compounds were evaluated for their *in vitro* and *ex vivo* activity against *M. tuberculosis* H37Rv. Compared to the parent molecule, some of the compounds synthesized showed higher efflux inhibitory capacity, less cytotoxicity, and a remarkable synergistic effect with anti-TB drugs both *in vitro* and in human macrophages, demonstrating their potential to be used as co-adjuvants for the treatment of tuberculosis.

Introduction

Tuberculosis (TB) is a highly contagious airborne disease resulting from infection with *Mycobacterium tuberculosis*. The World Health Organization (WHO) currently estimates that one-third of the world's population is infected with *M. tuberculosis*, and in 2013, approximately 210 000 human lives were lost to TB.¹ The global health impact of *M. tuberculosis* is exacerbated by HIV co-infection, making TB one of the major AIDS-related opportunistic diseases.² This shocking failure to control TB is due to the combination of many factors, among which: the non-compliance of the patients to the required six months of multidrug therapy; the difficulty to provide it in a sustained and properly-dosed regimen, particularly in those parts of the world that are the least equipped to deal with the disease.³ These issues have altogether led to the emergence of multidrug resistant (MDR) TB and extensively drug-resistant (XDR) TB. As

1
2
3 such, to address this global health crisis, the process of drug discovery must rely both on novel
4
5 chemical anti-TB entities^{4,5} and on an innovative approach that rationally prevents the raise of
6
7 drug resistance.
8
9

10 After many years without delivering any new anti-TB drug, the discovery of bedaquiline for
11
12 the treatment of MDR-TB, and a nourished pipeline of compounds already in clinical trials
13
14 (<http://www.newtbdrugs.org/pipeline.php>) have renewed hope for the treatment of TB and
15
16 especially MDR-TB. However, the lack of innovation in the overall therapeutic approach makes
17
18 quite predictable that mutation-based resistant strains will inexorably emerge also for these novel
19
20 drugs. The discovery of bedaquiline⁶ and pretomanid⁷ has showed that the whole cell phenotypic
21
22 assay of large libraries of compounds, and the wise medicinal chemistry efforts toward the
23
24 improvement of these molecules, are reliable methodological approaches to drive the research
25
26 towards novel anti-TB agents.⁸ Indeed, most of the efforts of some of the authors of this work
27
28 has moved through this path.⁹⁻¹⁹ While this approach has proved to be correct, it is nevertheless
29
30 incomplete. It does not consider that, besides mutations, other mechanisms such as efflux play an
31
32 important role in the development of resistance in *M. tuberculosis*.²⁰⁻²²
33
34
35
36
37

38 Efflux pumps are involved in several physiological processes such as detoxification of
39
40 intracellular metabolites and cellular homeostasis.²³ Simultaneously, they contribute to the
41
42 development of intrinsic and acquired drug resistance in many bacterial pathogens. Usually they
43
44 confer low-to-intermediate level of resistance, however, the constant pressure of subinhibitory
45
46 concentrations of the antibiotic promotes the selection of spontaneous mutants.²⁰ Therefore: *a)*
47
48 efflux pumps are effectors of the innate drug-resistance machinery; *b)* they are crucial in
49
50 conferring a low-level of drug resistance; *c)* they contribute to lower the concentration of the
51
52 drug inside the mycobacterial cell, enabling the emergence of a high-level of resistance; *d)* it has
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
been demonstrated that efflux inhibitors (EIs) are able to improve or restore the activity of old drugs towards which the bacteria had become resistant.²⁴

In spite of this knowledge, the extent to which an antimicrobial compound is a substrate of efflux is seldom measured, and it is not considered an important parameter in the hit-to-lead process for the optimization of novel anti-TB drugs. The recent discovery by Lee and colleagues of spectinamides as anti-TB drug candidates,²⁵ also by virtue of their scarce tendency to be extruded by efflux pumps, confirms the importance of taking into account efflux when the design of new drugs is planned.²⁶ In addition to these findings, although the mechanism of adaptation of *M. tuberculosis* to the hostile environment is still a matter of debate, Adams and colleagues have recently reported that bacterial efflux pumps mediate multi-drug tolerance and the bacterial survival in macrophages, leading to a long-lasting therapy.^{27,28}

It is therefore possible to claim that inhibition of efflux would lead to a number of beneficial effects: *a)* increasing the activity of the anti-TB drugs subject to efflux; *b)* keeping the concentration of a given drug at the therapeutic dose, minimizing the possibility to select mutants; *c)* drastically shorten the duration of treatment by reducing multi-drug tolerance. This could be priceless in order to repurpose old drugs and preserve the efficacy of those novel compounds, such as bedaquiline, that are either next to be introduced in the anti-TB arena or that already are.

Thioridazine (TZ) is a neuroleptic with efflux inhibitory properties,²⁹ that has attracted the attention of many researchers due to its ability to hit drug resistant strains.³⁰ In a clinical trial in Argentina, TZ was used for the treatment of patients with XDR-TB in combination with anti-TB drugs, with good results.³¹ It has been demonstrated that TZ has a dual effect against *M. tuberculosis*: it is an inhibitor of bacterial efflux pumps, and, also, it induces the acidification of

1
2
3 the phagosome, contributing to restriction of intracellular *M. tuberculosis* growth.^{30,32–34} TZ is
4
5 not the only inhibitor of efflux investigated for the treatment of TB. Recently chlorpromazine,
6
7 another neuroleptic with efflux inhibitory properties, was tested along with its metabolites
8
9 against *M. smegmatis* and exhibited synergistic activity when administered in combination with
10
11 known anti-TB drugs.^{35,36} Also the antiarrhythmic verapamil is an efflux pump inhibitor that has
12
13 been shown to have an antimicrobial-potentiating effect in the treatment of *M. tuberculosis* both
14
15 *in vitro* and *in vivo*.³⁷ It was shown that inhibition of the efflux pumps of *M. tuberculosis* by
16
17 verapamil reduces the bacterial drug tolerance induced in the intracellular compartment inside
18
19 the macrophages and in zebrafish granuloma-like lesions. Unfortunately, the use of TZ in the
20
21 therapy of TB is severely limited by its neuroleptic properties and a number of severe toxicity
22
23 issues. Inspired by these considerations, we herein report the design and synthesis of a number of
24
25 TZ derivatives, and their biological evaluation as efflux inhibitors and synergistic effect with
26
27 known anti-TB drugs both *in vitro* and on infected human monocyte-derived macrophages.
28
29 Among the novel compounds, when compared to the parent molecule TZ, compound **10** showed
30
31 higher efflux inhibitory ability, less toxicity, and a remarkable synergistic effect with first- and
32
33 second-line drugs, especially rifampicin. As such, it may represent an interesting starting point
34
35 for the development of more potent and less toxic efflux inhibitors to be used in combination
36
37 with the current first- and second-line anti-TB drugs.
38
39
40
41
42
43
44

45 **Rational design**

46
47 Since the lack of detailed information about the structure of the efflux systems, the new
48
49 compounds were prepared following a Ligand-Based Drug Design approach. TZ was used as
50
51 template, given its well-known and deeply investigated anti-TB properties when administered in
52
53 combination with first-line drugs, as mentioned above.^{29,32–34,38,39} The aim of this work was
54
55
56
57
58
59
60

1
2
3 therefore to chemically modify TZ in order to obtain a compound with improved adjuvant
4 properties while limiting the onset of side effects, especially at the CNS level. We reasoned that,
5
6 in first place, it was necessary to escape from the phenothiazine core because, according to the
7
8 SAR of antipsychotic drugs,⁴⁰ it is crucial in conferring the desired neuroleptic activity.
9
10 Moreover, although with a few exceptions,⁴¹ a series of TZ analogues in which the
11
12 phenothiazine core was kept intact has already been reported as inhibitors of efflux in other
13
14 bacteria, but with scarce results.^{38,42} In addition to this, efflux systems are known to be affine to
15
16 charged quaternary ammonium salts such as ethidium bromide (EtBr) and berberine, and to
17
18 molecules bearing basic amino groups (TZ, VP, reserpine), that likely occur to be protonated at
19
20 the acidic pH of the sites infected by *M. tuberculosis*. Given these premises, chemical
21
22 manipulation was carried out keeping intact the N-methylpiperidine moiety, whereas modifying
23
24 the nature of the heterocyclic attached to it and the length of the spacer.
25
26
27
28
29
30

31
32 Several heterocycles, embodying a variable number of rings, were attached by the nitrogen
33
34 atom to an N-methyl-2-piperidinyl appendage through an ethylene linker (compounds **9-15**, chart
35
36 1).

37
38 [Insert chart 1 here]

39
40
41 The carbazole (**9**) and the acridone (**12**), that are tricyclic flat structures, were chosen for their
42
43 close resemblance with the phenothiazine core. The indole (**10**), and the benzimidazole (**11**) are
44
45 among the most privileged scaffolds used in medicinal chemistry, and could afford extended
46
47 chemical manipulation of the series. The diphenylamines **13** and **14** were synthesized to check
48
49 whether the planar structure of the phenothiazine could be disrupted without loss of the
50
51 inhibitory activity. The pyrrolidine **15** was prepared to check whether a small ring could still be a
52
53 suitable substrate of efflux. Once the preliminary assays had corroborated the design of
54
55
56
57
58
59
60

1
2
3 compound **9**, other appendages were attached to the carbazole core in place of the N-methyl-2-
4 piperidinyl one. To start, a less polar and flatter substrate such as the 2-ethylpyridine (**18**) was
5 attached to the carbazole nitrogen; then, the distance between the nitrogen of carbazole and that
6 of the appendage was shortened by one methylene unit in compound **19**.
7
8
9
10
11

12 The synthesis of compounds **5** and **6** was accomplished in the attempt to couple a moiety that
13 is thought to be responsible for the EI activity to a potent anti-TB agent;^{11,16} this would have led
14 to the synthesis of the first rationally designed TB-GEI (Growth and Efflux Inhibitor), which
15 could represent a superior therapeutic option for the treatment of TB. Indeed, the recent finding
16 that bedaquiline, along with its antibacterial activity, is also a weak inhibitor of efflux
17 mechanisms, accounts for this reasoning.⁴³ Finally, since the recent interest in the use of VP and
18 its derivatives in the treatment of TB,^{44,45} we have tried to merge the two structures of TZ and
19 VP in one hybrid molecule (Figure 1), and therefore compounds **7** and **8** (chart 1) were
20 synthesized and tested.
21
22
23
24
25
26
27
28
29
30
31
32

33
34 [Insert Figure 1 here]
35

36 Chemistry

37
38 The synthesis of derivatives **5–15** was achieved through reaction of the suitable heterocyclic
39 precursor and 2-(2-chloroethyl)-N-methylpiperidine hydrochloride, in dry DMF using NaH in
40 excess, either at room temperature or heating for several hours, when necessary (Scheme 1).
41
42 When not commercially available, the synthesis of the heterocyclic precursors was achieved in
43 good yields according to a well-established procedure, as in the case of intermediates **1** and
44 **2**.^{13,16} Compound **3**⁴⁶ was prepared reacting 3,4-dimethoxyaniline with triethylamine and 2-
45 iodopropane in refluxing methanol, differently from what already reported. For the synthesis of
46 compound **18**, first 2-(hydroxymethyl)-pyridine was treated with *p*-toluensulfonyl chloride and
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 triethylamine in dichloromethane to give the tosyl derivative **16**, and then the ameliorated
4
5 leaving group is displaced by carbazole according to the conditions reported by Cheng (Scheme
6
7 2).⁴⁷ In the case of compound **19**, carbazole was first treated with dichloroethane to give N-
8
9 (chloroethyl)carbazole **17**, that was reacted with piperidine in DMF at room temperature using
10
11 K₂CO₃ as the base to give **19** (Scheme 2).⁴⁸ For the synthesis of compound **8**, 3,4-
12
13 dimethoxyphenyl acetonitrile was first treated with sodium hydride and 2-bromopropane to give
14
15 intermediate **4**;⁴⁹ several attempts to couple this derivative with 2-(2-chloroethyl)-N-
16
17 methylpiperidine hydrochloride with the use of various bases, performed according to different
18
19 literature protocols,⁴⁹⁻⁵¹ failed to yield the desired product. The synthesis was finally
20
21 accomplished by heating the two reagents in DMF in a microwave oven, using an excess of
22
23 sodium amide as the base. Interestingly, the same synthetic conditions did not give any product
24
25 with conventional heating also after many days at 120 °C. Compound **8** was tested preliminarily
26
27 as a racemic mixture.
28
29
30
31
32

33
34 [Insert Scheme 1 here]

35
36 [Insert Scheme 2 here]

37 38 **Results and Discussion.**

39
40 A total of 13 compounds were synthesized in this study (**5-15**, **18**, **19**, chart 1), that underwent
41
42 biological assays. In order to set up a faster and cheaper model for screening the activity of the
43
44 compounds, they were first evaluated for their antimycobacterial and efflux inhibitory activity
45
46 against *M. smegmatis* mc²155 reference strain. For those compounds showing inhibitory activity
47
48 higher than TZ, cytotoxicity on human-monocyte derived macrophages was assessed.
49
50 Compounds showing less cytotoxicity and higher efflux inhibitory activity than that of TZ, were
51
52 further evaluated on *M. tuberculosis* H37rv, as described herein.
53
54
55
56
57
58
59
60

Antimycobacterial and efflux inhibitory activity against *M. smegmatis* mc²155

The compounds were first tested for their capability to inhibit the growth of *M. smegmatis* strain mc²155 (Table 1). The compounds demonstrated extremely poor or absent antimycobacterial activity against *M. smegmatis*, especially if compared with TZ, which was used as positive control. This was considered a good result, as high bactericidal/bacteriostatic activity could bias the following experiments of synergy with first- and second-line anti-TB agents. Due to the reduced solubility and the low antimycobacterial activity, it was not possible to determine the exact MIC values for some compounds (*i.e.* **5-8**, **11**, **13**, **15**, **18**, **19**). As such, when bacterial growth is still noticed at the maximum concentration tested, the MIC was indicated by “>MIC”. For instance, >256 µg/mL means that the MIC of this compound is higher than 256 µg/mL, as it was technically impossible to determine it. After determining their MICs, the compounds were tested for their capability to inhibit efflux of EtBr from *M. smegmatis* mc²155 cells by real-time fluorometry, using TZ and VP as controls (Table 1, relative final fluorescence (RFF) values). According to a widely used protocol for this kind of assay,⁵² in order not to compromise the cellular viability, all of the compounds were tested at ½ of their MIC. For those compounds for which the exact MIC could not be determined (above reported), the last concentration value that could be technically determined was considered ½ of the MIC. Despite the small set of compounds prepared for this preliminary study, a few SAR considerations can be made. In general, the majority of the compounds bearing the N-methyl-2-piperidinyl appendage had inhibitory effect on the efflux of EtBr. We were pleased to notice that compound **7**, designed as a hybrid molecule resembling both VP and TZ, had a very good inhibitory activity of EtBr efflux. However, the same does not apply to the other hybrid compound **8**. It might be then speculated that the N-methyl-2-piperidinyl appendage must be attached, through an ethylene

1
2
3 linker, to another nitrogen atom of the heterocyclic, yielding a more polar structure. When the N-
4 methyl-2-piperidinyl appendage is attached through an ethylene linker either to tricyclic
5
6 (compounds **9**, **12**), bicyclic (compounds **10**, **11**) or more flexible ring structures (compounds **13**,
7
8 **14**), a good inhibitory activity, sometimes higher than that of the parent compound TZ, is
9
10 noticed. However, bulkier heterocyclic (compounds **5** and **6**) or small rings (compound **15**), have
11
12 a detrimental impact on the efflux inhibitory properties. Surprisingly, the benzimidazole
13
14 derivative **11** showed an exceptionally high activity, resulting by far more potent than VP. The
15
16 distance between the nitrogen of the appendage and that of the heterocyclic seems to have
17
18 pharmacological significance, since the activity of compound **19** is considerably low. Finally, the
19
20 presence of a tertiary aliphatic amino moiety seems to be determinant, being compound **18** the
21
22 least active of the series.
23
24
25
26
27
28

29 **Cytotoxicity evaluation of compounds 7, 9, 10, 11 and 12**

30
31
32 Compounds **7**, **9**, **10**, **11** and **12**, that resulted more active than TZ in inhibiting the efflux of
33
34 EtBr out of *M. smegmatis* cells, were evaluated against human-monocyte derived macrophages
35
36 to assess their *ex vivo* cytotoxicity toward eukaryotic cells (Table 1). We were pleased to notice
37
38 that, with the exception of compound **12** ($IC_{50} = 0.762 \mu\text{g/mL}$) all of the tested compounds were
39
40 found to be less cytotoxic than TZ in this assay. Compounds **9** and **10**, ($IC_{50} = 8.8 \mu\text{g/mL}$ and
41
42 $10.5 \mu\text{g/mL}$, respectively) are two-fold less cytotoxic than TZ ($IC_{50} = 5.6 \mu\text{g/mL}$), whereas
43
44 compounds **7** and **11** ($IC_{50} = 84.8 \mu\text{g/mL}$ and $170.8 \mu\text{g/mL}$) were found to be safe towards human
45
46 macrophages. Overall, these preliminary data clearly suggest that the replacement of the
47
48 phenothiazine core with other ring systems allows maintaining the efflux inhibitory activity with
49
50 the possibility to decrease the cytotoxicity.
51
52
53
54

55 [Insert Table 1 here]
56
57
58
59
60

1
2
3 [Insert Figure 2 here]
4

5 Compounds **7**, **9**, **10** and **11**, that resulted more active than TZ in inhibiting the efflux of EtBr
6 from *M. smegmatis*, and less cytotoxic against human-monocyte derived macrophages, were
7 selected for additional biological studies against *M. tuberculosis* H37Rv strain. Compound **12**,
8 although presenting higher RFF values than that of TZ, was excluded based on its higher
9 cytotoxicity.
10
11

12
13
14
15
16
17
18 **Evaluation of compounds 7, 9, 10 and 11 antimycobacterial and efflux inhibitory activity**
19 **against *M. tuberculosis* H37Rv**
20

21
22 Compounds **7**, **9**, **10** and **11** were tested against the pan-susceptible reference strain H37Rv,
23 following the same rationale used for *M. smegmatis*, *i.e.* the determination of antimycobacterial
24 activity and the evaluation of their effect on EtBr efflux (Table 2). As observed for *M.*
25 *smegmatis*, the selected derivatives showed no antimycobacterial activity against *M.*
26 *tuberculosis*, therefore excluding the possibility of bias during the following assays. With regard
27 to their activity as inhibitors of EtBr efflux, the compounds were tested with the same procedure
28 used as in the case of *M. smegmatis*. Compound **9** showed similar activity to that of TZ, whereas
29 compounds **7**, **10** and **11** were found to be 2-4 fold more potent than TZ, although less active
30 than VP (Table 2, Figure 2). Although quite active, the benzimidazole derivative **11** failed to
31 reproduce the extraordinary efflux inhibitory effect observed against *M. smegmatis*. This is not
32 surprising and can be somehow explained on the basis of the faster metabolism of *M. smegmatis*
33 compared to that of *M. tuberculosis*, that accounts for the higher susceptibility to the efflux
34 inhibitory effect. Our own experience shows that RFF values are always scaled down in *M.*
35 *tuberculosis* in comparison to those observed for the same compounds in *M. smegmatis*, although
36 maintaining the inhibitory relation.^{53,54} Regardless, we can claim that, in the conditions reported,
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 all of the tested compounds have maintained their superior capability of inhibiting efflux
4
5 compare to TZ against *M. tuberculosis*.
6
7

8 [Insert Table 2 here]
9

10 **Evaluation of synergistic effect of the selected TZ analogues in combination with first-**
11 **and second-line anti-TB drugs and determination of the fractional inhibitory concentration**
12 **(FIC).**
13
14
15
16

17 Once that the inhibition of efflux was confirmed, the study went ahead evaluating compounds
18 **7, 9, 10** and **11** for their effect in combination with the current first-line (isoniazid, INH;
19 rifampicin, RIF) and second-line (amikacin, AMK; ofloxacin, OFX) drugs used for the treatment
20 of TB. Their effect was also tested in combination with EtBr, to correlate its efflux with the
21 efflux of the anti-TB drugs.⁵⁵ The MICs of INH, RIF, AMK and OFX were calculated in the
22 absence and in the presence of scalar sub-inhibitory concentrations of each compound against *M.*
23 *tuberculosis* H37Rv, that is known to have intrinsic and readable efflux activity of these anti-TB
24 drugs.^{22,54} (Table 3).
25
26
27
28
29
30
31
32
33
34
35

36 [Insert Table 3 here]
37
38

39 Initially, compounds **7, 9, 10** and **11** were tested at $\frac{1}{2}$ of their MIC (see Table 3 for details),
40 and then, according to the protocol widely used for this sort of investigations,⁵² they were tested
41 by two-dimensional broth microdilution checkerboard assay, to evaluate the extent of the
42 synergism. Also in this case, as already explained in the case of the efflux inhibition assays, for
43 those compounds for which the exact MIC could not be determined, $\frac{1}{2}$ of the MIC was
44 considered the concentration that was equal to the highest concentration where it was obtained
45 growth. When tested at these concentrations, all of the newly synthesized compounds and the
46 controls demonstrated very high synergistic effect with both the antibiotics and EtBr. In this
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 case, the MIC values of INH, RIF, AMK, OFX and EtBr could be reduced more than 64-fold
4 (Table 3). Compound **10**, for which the inhibitory effect on efflux was already assessed, had in
5
6 general a very high synergistic effect with the tested drugs and, in particular, with RIF. In fact,
7
8 compound **10** was able to improve the activity of RIF by 4-fold at concentrations as low as 8
9
10 $\mu\text{g/mL}$ (approx. 1/64 of its MIC), demonstrating a potent synergistic effect. Moreover, at a
11
12 concentration of 64 $\mu\text{g/mL}$ (approx. 1/8 of its MIC), compound **10** was also able to improve the
13
14 activity of AMK and OFX by more than 128-fold, and EtBr by 8-fold (Table 3). Importantly, we
15
16 have noticed that the synergistic activity demonstrated by the compounds in combination with
17
18 EtBr correlates well with the results obtained with the inhibition of EtBr efflux by RFF.
19
20
21
22
23

24
25 One may argue that TZ, considering the absolute concentrations at which the synergistic
26
27 activity is measured, is slightly more active than compound **10**. However, seen under a more
28
29 widespread perspective, compound **10** is less toxic, more active with regard the inhibition of
30
31 efflux, and unlikely to possess CNS-related properties. This can be considered a good
32
33 achievement, in particular considering that the aim of this paper was the selection of compounds
34
35 devoid of antimycobacterial activity, with reduced toxicity to the human macrophage and with
36
37 higher efflux inhibitory capability, so as to promote the antimycobacterial activity of the anti-TB
38
39 drugs and be considered as a future adjuvant in the fighting against TB.
40
41
42

43
44 Surprisingly, despite the high activity in inhibiting the efflux, compound **11** was found to be
45
46 not active in the combination assay. Compounds **7** and **9** were found to be slightly less active
47
48 than **10** in the combination assay; however, in the case of compound **7**, it must be noticed that it
49
50 is able to improve the activity of RIF by 4-fold also at very low concentrations. It is intriguing to
51
52 notice that compounds **7** and **9**, as compound **10**, demonstrated to have a significant synergistic
53
54 effect in particular with RIF. The reason of this preferred synergism is worth of further
55
56
57
58
59
60

1
2
3 investigation but, at this moment, it can only be speculated that **10**, as well as the other
4 derivatives belonging to this series, although to a lesser extent, have high affinity for interfering
5 with efflux systems that extrude RIF. However, it cannot be ruled out that the two derivatives
6
7
8 interfere with other mechanism of resistance used by the cell in the presence of RIF. Finally, it is
9
10 worth of consideration the fact that compounds **7**, **9** and **10** were more active in the combination
11
12 assay that VP, another drug often investigated for its potential role as adjuvant in the TB
13
14 treatment.
15
16
17
18

19
20 The synergistic activity between the compounds was also represented as the fractional
21 inhibitory concentration (FIC), that is a value expressing the synergistic activity of the
22 compounds in combination with the antibiotics and EtBr (Figure 3). FIC was determined for
23 each anti-TB drug by dividing the MIC of each drug when used in combination, by the MIC of
24 each drug used alone. Since a drug cannot interact with itself, the effect of a self-drug
25 combination will always be additive, with an FIC index of 1. As such, when the FIC value is
26
27 lower than 0.25, a synergistic effect is noticed between the modulator and the antimicrobial.
28
29 When above 2, there is antagonism between the compounds tested, whereas within these two FIC
30
31 values, indifference is noticed.²⁴
32
33
34
35
36
37
38
39

40
41 [Insert figure 3 here]
42

43
44 Isobolograms were constructed, by plotting changes in the MIC of antibiotics as a function of
45 the tested compounds concentration (Figure 3 and S1 – example for compound **10**). As it can be
46
47 seen, for the majority of the combinations of compound **10** with the antibiotics synergy was
48
49 observed, with FIC values ranging from 1 to not possible to determine (ND) due to the very high
50
51 synergistic effect, depending on the antibiotic combination (see legend of Figure 3 supporting
52
53 information for details).
54
55
56
57
58
59
60

Evaluation of the intracellular anti-TB activity of the selected TZ analogues.

Finally, we evaluated the intracellular antimycobacterial activity of compounds **7**, **9**, **10** and **11** alone and in combination with INH or RIF against *M. tuberculosis*-infected human monocyte-derived macrophages (Figure 4). This assay is a fair reproduction of what actual happens during the TB infection, and therefore it can help in obtaining a clearer idea of the potential of our compounds. INH and RIF were used at $\frac{1}{2}$ of its MIC (0.05 and 0.5 $\mu\text{g/mL}$, respectively), therefore having no direct inhibitory effect on the bacteria at these concentrations. The compounds **7**, **9**, **10** and **11** were tested at nontoxic concentrations (16 $\mu\text{g/mL}$, 0.078 $\mu\text{g/mL}$; 1.25 $\mu\text{g/mL}$, and 40 $\mu\text{g/mL}$, respectively) determined against human-monocyte derived macrophages (Figure S2). Above these concentrations, macrophage viability is reduced below 90%, nullifying the assay. At these concentrations, the compounds tested showed to be devoid of any antimycobacterial activity against intracellular *M. tuberculosis*. Consistent with the findings above reported, we were pleased to notice that the co-administration of the compounds with INH or RIF (at a non-antibiotic inhibitory concentration) led to a strong enhancement of the killing activity of the human macrophages against the H37Rv strain. This is comparable with the results previously obtained with TZ and other efflux inhibitors that has been shown to have a dual bacterial-host boosting effect against *M. tuberculosis*.⁵⁶

Conclusion

The contribution of efflux systems to *M. tuberculosis* drug resistance and tolerance has been increasingly recognized, although only a few medicinal chemistry efforts have been made towards the synthesis of *M. tuberculosis* efflux inhibitors. Despite the amount of literature establishing TZ as a valuable agent against TB, the numerous toxicity issues have always hampered its safe administration as an adjuvant of TB therapy. To our knowledge, this is the first

1
2
3 medicinal chemistry campaign aimed at modifying TZ with regard to its potential as adjuvant of
4 TB therapy, with specific assays such as the determination of the efflux inhibition and the
5 synergistic activity in combination with known anti-TB drugs both *in vitro* and *ex vivo*.
6
7 Compared to TZ, the representative derivatives tested were found to be less toxic toward human
8 macrophages, ranging from two-fold (compound **9** and **10**) to more than 50-fold (compound **11**).
9
10 Compound **7**, intended as a hybrid of TZ and VP, showed a higher inhibitory activity than that of
11 TZ itself and much less toxicity, therefore confirming the rationale of the design. More
12 importantly, we have escaped from the phenothiazine scaffold, thus assuming a reduction of the
13 onset of side effects at the CNS level. The newly synthesized compounds showed high
14 synergistic activity when tested in combination with some of the most important first-line (INH,
15 RIF) and second-line (AMK, OFX) drugs used for the treatment of TB. In particular compound
16 **10** was able to improve the activity of RIF at concentration as low as approximately 1/64 of its
17 MIC. Additionally, these compounds were able to improve the activity of INH and RIF against
18 intracellular *M. tuberculosis*. Considering the data on inhibition of EtBr efflux, coupled to the
19 low antimycobacterial activity, it might be claimed that the synergetic activity is due to their
20 ability to hamper the intrinsic mycobacterial drug efflux.
21
22

23
24 Finally, we confirmed *M. smegmatis* mc²155 as a suitable surrogate of *M. tuberculosis* for the
25 preliminary assessment the efflux inhibitory activity, at a lower cost and time consuming rate.
26 Altogether, these findings provide a solid base to further investigate compound **10** as a booster of
27 the antimycobacterial chemotherapy when associated with first- and second-line drugs, by virtue
28 of its capability to block the intrinsic efflux activity of mycobacteria. This might represent a
29 lateral approach toward the cure of TB. Studies expanding this versatile series and its mechanism
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of action and activity toward *M. tuberculosis* drug resistant strains, especially resistant to
4
5
6 isoniazid and rifampicin (MDR-TB), are currently underway in our research groups.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EXPERIMENTAL PART

Chemistry

General information. All the reagents were purchased from Sigma-Aldrich, Alfa-Aesar and Enamine at reagent purity and, unless otherwise noted, were used without any further purification. Dry solvents used in the reactions were obtained by distillation of technical grade materials over appropriate dehydrating agents. MCRs were performed using CEM Microwave Synthesizer-Discover model. Reactions were monitored by thin layer chromatography on silica gel-coated aluminium foils (silica gel on Al foils, SUPELCO Analytical, Sigma-Aldrich) at both 254 and 365 nm wavelengths. When indicated, intermediates and final products were purified through silica gel flash chromatography (silica gel, 0.040-0.063 mm), using appropriate solvent mixtures.

¹H-NMR and ¹³C-NMR spectra were recorded on a BRUKER AVANCE spectrometer at 300, 400 and 100 MHz respectively, with TMS as internal standard. ¹H-NMR spectra are reported in this order: multiplicity and number of protons. Standard abbreviation indicating the multiplicity was used as follows: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quadruplet, m = multiplet and br = broad signal. HPLC/MS experiments were performed with HPLC: Agilent 1100 series, equipped with a Waters Symmetry C18, 3.5 μm, 4.6 mm x 75 mm column and MS: Applied Biosystem/MDS SCIEX, with API 150EX ion source. HRMS experiments were performed with LTQ ORBITRAP XL THERMO.

All compounds were tested as 95% purity samples or higher (by HPLC/MS).

The synthesis and chemical characterizations of intermediates 1-4, 16, 17 is reported in the Supporting Information.

1
2
3 **General procedure for the synthesis of compounds 5, 6, 9-15, 18.** To a suspension of
4 sodium hydride (60% suspension in mineral oil, 3 eq) in DMF (5 mL/mmol) was added the
5 suitable heterocyclic compound (1 eq) at 0 °C. Reaction mixture was stirred for 15 minutes at the
6 same temperature and then 2-(2-chloroethyl)-piperidine hydrochloride (1.3 eq) was added
7 portion wise. The mixture was allowed to react at room temperature until consumption of the
8 starting material. In some cases (**5, 6, 13**) reflux heating was necessary. After quenching with
9 water, the mixture was extracted with ethyl acetate (3 × 10 mL), and the organic layers were
10 washed with water and brine, dried over anhydrous Na₂SO₄ and concentrated under reduced
11 pressure. The crude material was purified through flash chromatography. Reaction times and
12 conditions, yields, purification methods and other analytical data are reported in the supporting
13 information.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **N-isopropyl-3,4-dimethoxy-N-(2-(1-methylpiperidin-2-yl)ethyl)aniline (7).** To a solution of
30 **3** (60 mg; 0.38 mmol) in dry toluene (2 mL) was added sodium amide (120 mg; 3.07 mmol) and
31 2-(2-chloroethyl)piperidine hydrochloride (244 mg; 1.23 mmol). The reaction mixture was
32 stirred and heated in a microwave oven at 140 °C for 30 minutes. After quenching with brine (25
33 mL), the mixture was extracted with ethyl acetate (3 × 10 mL), and the combined organic layers
34 were dried over anhydrous Na₂SO₄ and evaporated under reduced pressure. The crude material
35 was then purified through flash chromatography eluting with dichloromethane/methanol 9:1.
36 Yield: 16%. ¹H-NMR (400 MHz-CDCl₃): □ 1.10-1.15 (m, 6 H); 1.20-1.87 (m; 8H), 2.30-2.35
37 (bs; 5H); 2.95-3.10 (m; 2H), 3.15-3.25 (m, 1H); 3.65-3.75 (m, 1H); 3.84 (s, 3H); 3.87, (s, 3H);
38 6.41 (d, J = 9 Hz, 1H); 6.49 (s, 1H); 6.79 (d, J = 9 Hz, 1H). ¹³C-NMR (100.6 MHz-CDCl₃): □
39 19.4, 20.2, 23.3, 28.3, 41.3, 53.8, 55.9, 56.3, 105.6, 111.9, 142.6, 143.7, 149.5. HRMS (ESI)
40 calculated for C₁₉H₃₂N₂O₂ [M + H]⁺ 321,2464, found 321.25365.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
2-(3,4-Dimethoxyphenyl)-2-isopropyl-4-(1-methylpiperidin-2-yl)butanenitrile (8). To a solution of **4** (70 mg; 0.31 mmol) in dry toluene (2 mL) was added sodium amide (124 mg; 3.19 mmol) and 2-(2-chloroethyl)piperidine hydrochloride (252 mg; 1.25 mmol). The reaction mixture was stirred and heated in a microwave oven at 140 °C for 30 minutes. After quenching with brine (25 mL), the mixture was extracted with ethyl acetate (3 × 10 mL), and the combined organic layers were dried over anhydrous Na₂SO₄. The crude material was then purified through flash column chromatography eluting with dichloromethane/methanol 9:1. Yield: 50%. ¹H-NMR (300 MHz-CDCl₃): □ 0.8 (dd, J₁ = 4 Hz, J₂ = 7 Hz, 3 H); 1.23-1.80 (m; 11H), 1.85-2.40 (m; 8H); 2.80-2.95 (m; 1H), 3.88 (s, 3H); 3.90 (s, 3H); 6.80-7.00 (m, 3H). ¹³C-NMR (100.6 MHz-CDCl₃): □ 18.7, 19.0, 24.0, 28.2, 29.9, 32.1, 32.5, 37.9, 53.4, 55.9, 56.0, 63.0, 109.1, 109.4, 111.0, 118.8, 121.1, 130.5, 148.3, 149.0. HRMS (ESI) calculated for C₂₁H₃₂N₂O₂ [M + H]⁺ 345,2464, found 345.25365.

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9-(2-(Piperidin-1-yl)ethyl)-9H-carbazole (19). To a solution of piperidine (33 μl; 0.33 mmol) in DMF (15 mL/mmol) was added potassium carbonate (138 mg, 1 mmol), this mixture was stirred at room temperature for 20 minutes and then the intermediate **17** (10 mg, 0.43 mmol) was added. Reaction mixture was stirred to 60 °C overnight. After cooling, brine (25 mL) was added and the mixture was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with water and brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude material was purified through flash chromatography eluting with petroleum ether/ethyl acetate 95/5, yielding the title compound as a white solid. Yield: 19%. ¹H-NMR (400 MHz-CDCl₃): □ 1.24-1.60 (m, 6H); 3.07 (bs, 2H); 3.39 (bs, 2H); 4.49 (t, J = 8 Hz, 2H); 4.62 (t, J = 8 Hz, 2H); 7.23-7.28 (m, 2H); 7.46-7.79 (m, 4H), 8.12 (d, J = 8 Hz, 2H). ¹³C-NMR (100.6

1
2
3 MHz-CDCl₃): □ 24.2, 25.4, 42.1, 44.7, 62.8, 108.7, 119.1, 120.3, 123.0, 125.7, 140.5, 155.0.

4
5
6 HRMS (ESI) calculated for C₁₉H₂₂N₂ [M + H]⁺ 279,1783, found 279.39258

7 8 **Biology**

9 10 **Evaluation of the novel synthesized compounds against mycobacteria**

11 12 **Reagents and mycobacterial strains**

13
14
15 Thioridazine (TZ), verapamil (VP), isoniazid (INH), rifampicin (RIF), amikacin (AMK),
16
17 ofloxacin (OFX), EtBr, phosphate-buffered saline (PBS), and glucose were purchased from
18
19 Sigma-Aldrich (St. Louis, MO, USA). All solutions were prepared in deionized water, except
20
21 rifampicin and the TZ analogues **5-15**, **18** and **19**, which were prepared in DMSO. All solutions
22
23 were prepared on the day of the experiment. Middlebrook 7H9 (MB7H9) and the OADC
24
25 supplement (oleic acid/albumin/dextrose/catalase) were purchased from Difco (Madrid, Spain)
26
27 and Becton and Dickinson (Sparks, MD, USA) respectively. The mycobacterial reference strains
28
29 *M. smegmatis* mc²155 ATCC700084 and *M. tuberculosis* H37Rv ATCC27294^T were used to
30
31 evaluate the biologic activity of TZ analogues.
32
33
34
35

36
37 The determination of the minimum inhibitory concentration (MIC), the evaluation of the
38
39 synergistic effect of TZ analogues **7**, **9**, **10** and **11** with selected antibiotics and EtBr by broth
40
41 microdilution checkerboard assay, the evaluation of efflux inhibitory activity of the compounds
42
43 by real-time fluorometry and the cytotoxicity evaluation are reported in detail in the Supporting
44
45 Information.
46
47

48 **References**

49
50 (1) WHO | Global tuberculosis report 2014
51
52 http://www.who.int/tb/publications/global_report/en/ (accessed Feb 5, 2015).
53
54
55
56
57
58
59
60

1
2
3 (2) CDC - Reported Tuberculosis in the United States, 2011 - TB
4
5 <http://www.cdc.gov/tb/statistics/reports/2011/default.htm> (accessed Feb 5, 2015).
6
7

8
9 (3) WHO | Multidrug-resistant tuberculosis (MDR-TB)
10
11 <http://www.who.int/tb/challenges/mdr/en/> (accessed Feb 5, 2015).
12
13

14 (4) Duncan, K. Progress in TB Drug Development and What Is Still Needed. *Tuberc. Edinb. Scotl.* **2003**, *83* (1-3), 201–207.
15
16
17

18
19 (5) PLOS guest blogger, Urgency Needed in the Global Response to Drug-resistant
20 Tuberculosis [http://blogs.plos.org/speakingofmedicine/2013/11/01/urgency-needed-in-the-](http://blogs.plos.org/speakingofmedicine/2013/11/01/urgency-needed-in-the-global-response-to-drug-resistant-tuberculosis/)
21
22 [global-response-to-drug-resistant-tuberculosis/](http://blogs.plos.org/speakingofmedicine/2013/11/01/urgency-needed-in-the-global-response-to-drug-resistant-tuberculosis/) (accessed Mar 20, 2014).
23
24
25
26

27
28 (6) Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H. W. H.; Neefs, J.-M.; Winkler,
29 H.; Gestel, J. V.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; Chaffoy, D. de; Huitric, E.;
30 Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A Diarylquinoline Drug
31 Active on the ATP Synthase of Mycobacterium Tuberculosis. *Science* **2005**, *307* (5707), 223–
32 227.
33
34
35
36
37
38

39
40 (7) Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.;
41 Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B.
42 N.; Barry, C. E.; Baker, W. R. A Small-Molecule Nitroimidazopyran Drug Candidate for the
43 Treatment of Tuberculosis. *Nature* **2000**, *405* (6789), 962–966.
44
45
46
47
48
49

50
51 (8) Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for Bad Bugs:
52 Confronting the Challenges of Antibacterial Discovery. *Nat. Rev. Drug Discov.* **2007**, *6* (1), 29–
53 40.
54
55
56
57
58
59
60

1
2
3 (9) Lilienkampf, A.; Pieroni, M.; G. Franzblau, S.; R. Bishai, W.; P. Kozikowski, A.
4
5 Derivatives of 3-Isoxazolecarboxylic Acid Esters - A Potent and Selective Compound Class
6
7
8 against Replicating and Nonreplicating Mycobacterium Tuberculosis. *Curr. Top. Med. Chem.*
9
10 **2012**, *12* (7), 729–734.

11
12
13 (10) Lilienkampf, A.; Pieroni, M.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P.
14
15 Rational Design of 5-Phenyl-3-Isoxazolecarboxylic Acid Ethyl Esters as Growth Inhibitors of
16
17
18 *Mycobacterium Tuberculosis* . A Potent and Selective Series for Further Drug Development. *J.*
19
20
21 *Med. Chem.* **2010**, *53* (2), 678–688.

22
23
24 (11) Lun, S.; Guo, H.; Onajole, O. K.; Pieroni, M.; Gunosewoyo, H.; Chen, G.; Tipparaju, S.
25
26
27
28 K.; Ammerman, N. C.; Kozikowski, A. P.; Bishai, W. R. Indoleamides Are Active against Drug-
29
30
31 Resistant Mycobacterium Tuberculosis. *Nat. Commun.* **2013**, *4*, 2907.

32
33 (12) Mao, J.; Yuan, H.; Wang, Y.; Wan, B.; Pieroni, M.; Huang, Q.; van Breemen, R. B.;
34
35
36
37
38
39
40
41 Kozikowski, A. P.; Franzblau, S. G. From Serendipity to Rational Antituberculosis Drug
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

(12) Mao, J.; Yuan, H.; Wang, Y.; Wan, B.; Pieroni, M.; Huang, Q.; van Breemen, R. B.;
Kozikowski, A. P.; Franzblau, S. G. From Serendipity to Rational Antituberculosis Drug
Discovery of Mefloquine-Isoxazole Carboxylic Acid Esters. *J. Med. Chem.* **2009**, *52* (22), 6966–
6978.

(13) Onajole, O. K.; Pieroni, M.; Tipparaju, S. K.; Lun, S.; Stec, J.; Chen, G.; Gunosewoyo,
H.; Guo, H.; Ammerman, N. C.; Bishai, W. R.; Kozikowski, A. P. Preliminary Structure–
Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide
Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium Tuberculosis Strains.
J. Med. Chem. **2013**, *56* (10), 4093–4103.

(14) Pieroni, M.; Lilienkampf, A.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P.
Synthesis, Biological Evaluation, and Structure–Activity Relationships for 5-[(*E*)-2-

1
2
3 Arylethenyl]-3-Isoxazolecarboxylic Acid Alkyl Ester Derivatives as Valuable Antitubercular
4
5 Chemotypes. *J. Med. Chem.* **2009**, *52* (20), 6287–6296.

6
7
8
9 (15) Pieroni, M.; Lilienkamp, A.; Wang, Y.; Wan, B.; Cho, S.; Franzblau, S. G.; Kozikowski,
10
11 A. P. NOC Chemistry for Tuberculosis-Further Investigations on the Structure-Activity
12
13 Relationships of Antitubercular Isoxazole-3-Carboxylic Acid Ester Derivatives. *ChemMedChem*
14
15 **2010**, *5* (10), 1667–1672.

16
17
18
19 (16) Pieroni, M.; Tipparaju, S. K.; Lun, S.; Song, Y.; Sturm, A. W.; Bishai, W. R.;
20
21 Kozikowski, A. P. Pyrido[1,2-*a*]benzimidazole-Based Agents Active Against Tuberculosis (TB),
22
23 Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB. *ChemMedChem*
24
25 **2011**, *6* (2), 334–342.

26
27
28
29 (17) Stec, J.; Huang, Q.; Pieroni, M.; Kaiser, M.; Fomovska, A.; Mui, E.; Witola, W. H.;
30
31 Bettis, S.; McLeod, R.; Brun, R.; Kozikowski, A. P. Synthesis, Biological Evaluation, and
32
33 Structure–Activity Relationships of *N*-Benzoyl-2-Hydroxybenzamides as Agents Active against
34
35 *P. Falciparum* (K1 Strain), Trypanosomes, and Leishmania. *J. Med. Chem.* **2012**, *55* (7), 3088–
36
37 3100.

38
39
40
41
42 (18) Tabarrini, O.; Sabatini, S.; Massari, S.; Pieroni, M.; Franzblau, S. G.; Cecchetti, V. 6-
43
44 Hydrogen-8-Methylquinolones Active Against Replicating and Non-Replicating *Mycobacterium*
45
46 *Tuberculosis*: Antimycobacterial 6-Desfluoroquinolones. *Chem. Biol. Drug Des.* **2012**, *80* (5),
47
48 781–786.

49
50
51
52 (19) Tipparaju, S. K.; Joyasawal, S.; Pieroni, M.; Kaiser, M.; Brun, R.; Kozikowski, A. P. In
53
54 Pursuit of Natural Product Leads: Synthesis and Biological Evaluation of 2-[3-Hydroxy-2-[(3-
55
56 Hydroxypyridine-2-Carbonyl)amino]phenyl]benzoxazole-4-Carboxylic Acid (A-33853) and Its
57
58
59
60

1
2
3 Analogues: Discovery of *N*-(2-Benzoxazol-2-Ylphenyl)benzamides as Novel Antileishmanial
4 Chemotypes. *J. Med. Chem.* **2008**, *51* (23), 7344–7347.

7
8
9 (20) Machado, D.; Couto, I.; Perdigão, J.; Rodrigues, L.; Portugal, I.; Baptista, P.; Veigas, B.;
10 Amaral, L.; Viveiros, M. Contribution of Efflux to the Emergence of Isoniazid and Multidrug
11 Resistance in Mycobacterium Tuberculosis. *PloS One* **2012**, *7* (4), e34538.

16
17 (21) Louw, G. E.; Warren, R. M.; Gey van Pittius, N. C.; McEvoy, C. R. E.; Van Helden, P.
18 D.; Victor, T. C. A Balancing Act: Efflux/influx in Mycobacterial Drug Resistance. *Antimicrob.*
19 *Agents Chemother.* **2009**, *53* (8), 3181–3189.

24
25 (22) Silva, P. E. A. da; Groll, A. V.; Martin, A.; Palomino, J. C. Efflux as a Mechanism for
26 Drug Resistance in Mycobacterium Tuberculosis. *FEMS Immunol. Med. Microbiol.* **2011**, *63* (1),
27 1–9.

32
33 (23) Webber, M. A.; Piddock, L. J. V. The Importance of Efflux Pumps in Bacterial Antibiotic
34 Resistance. *J. Antimicrob. Chemother.* **2003**, *51* (1), 9–11.

38
39 (24) Coelho, T.; Machado, D.; Couto, I.; Maschmann, R.; Ramos, D.; von Groll, A.; Rossetti,
40 M. L.; Silva, P. A.; Viveiros, M. Enhancement of Antibiotic Activity by Efflux Inhibitors against
41 Multidrug Resistant Mycobacterium Tuberculosis Clinical Isolates from Brazil. *Front.*
42 *Microbiol.* **2015**, *6*, 330.

48
49 (25) Lee, R. E.; Hurdle, J. G.; Liu, J.; Bruhn, D. F.; Matt, T.; Scherman, M. S.; Vaddady, P.
50 K.; Zheng, Z.; Qi, J.; Akbergenov, R.; Das, S.; Madhura, D. B.; Rathi, C.; Trivedi, A.; Villellas,
51 C.; Lee, R. B.; Rakesh; Waidyarachchi, S. L.; Sun, D.; McNeil, M. R.; Ainsa, J. A.; Boshoff, H.
52 I.; Gonzalez-Juarrero, M.; Meibohm, B.; Böttger, E. C.; Lenaerts, A. J. Spectinamides: A New
53
54
55
56
57
58
59
60

1
2
3 Class of Semisynthetic Antituberculosis Agents That Overcome Native Drug Efflux. *Nat. Med.*
4
5 **2014**, *20* (2), 152–158.

6
7
8
9 (26) Viveiros, M.; Pieroni, M. Spectinamides: A Challenge, a Proof, and a Suggestion. *Trends*
10
11 *Microbiol.* **2014**, *22* (4), 170–171.

12
13
14 (27) Adams, K. N.; Takaki, K.; Connolly, L. E.; Wiedenhof, H.; Winglee, K.; Humbert, O.;
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Edelstein, P. H.; Cosma, C. L.; Ramakrishnan, L. Drug Tolerance in Replicating Mycobacteria
Mediated by a Macrophage-Induced Efflux Mechanism. *Cell*, **2011**, *145* (1), 39–53.

(28) Adams, K. N.; Szumowski, J. D.; Ramakrishnan, L. Verapamil, and Its Metabolite
Norverapamil, Inhibit Macrophage-Induced, Bacterial Efflux Pump-Mediated Tolerance to
Multiple Anti-Tubercular Drugs. *J. Infect. Dis.* **2014**, *210*: 456-66.

(29) Rodrigues, L.; Wagner, D.; Viveiros, M.; Sampaio, D.; Couto, I.; Vavra, M.; Kern, W.
V.; Amaral, L. Thioridazine and Chlorpromazine Inhibition of Ethidium Bromide Efflux in
Mycobacterium Avium and Mycobacterium Smegmatis. *J. Antimicrob. Chemother.* **2008**, *61* (5),
1076–1082.

(30) Martins, M.; Viveiros, M.; Kristiansen, J. E.; Molnar, J.; Amaral, L. The Curative
Activity of Thioridazine on Mice Infected with Mycobacterium Tuberculosis. *Vivo Athens*
Greece **2007**, *21* (5), 771–775.

(31) Abbate, E.; Vescovo, M.; Natiello, M.; Cufre, M.; Garcia, A.; Montaner, P. G.;
Ambroggi, M.; Ritacco, V.; Soolingen, D. van. Successful Alternative Treatment of Extensively
Drug-Resistant Tuberculosis in Argentina with a Combination of Linezolid, Moxifloxacin and
Thioridazine. *J. Antimicrob. Chemother.* **2012**, *67* (2), 473–477.

1
2
3 (32) Amaral, L.; Martins, M.; Viveiros, M. Enhanced Killing of Intracellular Multidrug-
4 Resistant Mycobacterium Tuberculosis by Compounds That Affect the Activity of Efflux Pumps.
5
6

7
8 *J. Antimicrob. Chemother.* **2007**, *59* (6), 1237–1246.
9

10
11 (33) Amaral, L.; Viveiros, M. Why Thioridazine in Combination with Antibiotics Cures
12 Extensively Drug-Resistant Mycobacterium Tuberculosis Infections. *Int. J. Antimicrob. Agents*
13
14 **2012**, *39* (5), 376–380.
15
16

17
18 (34) Martins, M.; Viveiros, M.; Couto, I.; Amaral, L. Targeting Human Macrophages for
19 Enhanced Killing of Intracellular XDR-TB and MDR-TB. *Int. J. Tuberc. Lung Dis. Off. J. Int.*
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (38) Martins, M.; Schelz, Z.; Martins, A.; Molnar, J.; Hajös, G.; Riedl, Z.; Viveiros, M.;
4 Yalcin, I.; Aki-Sener, E.; Amaral, L. In Vitro and Ex Vivo Activity of Thioridazine Derivatives
5 against Mycobacterium Tuberculosis. *Int. J. Antimicrob. Agents* **2007**, *29* (3), 338–340.
6
7

8
9
10
11 (39) Martins, M.; Viveiros, M.; Amaral, L. Inhibitors of Ca²⁺ and K⁺ Transport Enhance
12 Intracellular Killing of M. Tuberculosis by Non-Killing Macrophages. *Vivo Athens Greece* **2008**,
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(40) Aftab, D. T.; Ballas, L. M.; Loomis, C. R.; Hait, W. N. Structure-Activity Relationships
of Phenothiazines and Related Drugs for Inhibition of Protein Kinase C. *Mol. Pharmacol.* **1991**,
40 (5), 798–805.

(41) Salie, S.; Hsu, N.-J.; Semanya, D.; Jardine, A.; Jacobs, M. Novel Non-Neuroleptic
Phenothiazines Inhibit Mycobacterium Tuberculosis Replication. *J. Antimicrob. Chemother.*
2014, *69* (6), 1551–1558.

(42) Takács, D.; Cerca, P.; Martins, A.; Riedl, Z.; Hajós, G.; Molnár, J.; Viveiros, M.; Couto,
I.; Amaral, L. Evaluation of Forty New Phenothiazine Derivatives for Activity Against Intrinsic
Efflux Pump Systems of Reference Escherichia Coli, Salmonella Enteritidis, Enterococcus
Faecalis and Staphylococcus Aureus Strains. *In Vivo* **2011**, *25* (5), 719–724.

(43) Lu, P.; Villellas, C.; Koul, A.; Andries, K.; Lill, H.; Bald, D. The ATP Synthase Inhibitor
Bedaquiline Interferes with Small-Molecule Efflux in Mycobacterium Smegmatis. *J. Antibiot.*
(Tokyo) **2014**, *67* (12), 835–837.

1
2
3 (44) Gupta, S.; Tyagi, S.; Almeida, D. V.; Maiga, M. C.; Ammerman, N. C.; Bishai, W. R.
4
5 Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux
6
7 Inhibitor. *Am. J. Respir. Crit. Care Med.* **2013**, *188* (5), 600–607.
8
9

10
11 (45) Gupta, S.; Tyagi, S.; Bishai, W. R. Verapamil Increases the Bactericidal Activity of
12
13 Bedaquiline against Mycobacterium Tuberculosis in a Mouse Model. *Antimicrob. Agents*
14
15 *Chemother.* **2015**, *59* (1), 673–676.
16
17

18
19 (46) Kumar, H. M. S.; Reddy, B. V. S.; Anjaneyulu, S.; Yadav, J. S. A Novel and Efficient
20
21 Approach to Mono-N-Alkyl Anilines via Addition of Grignard Reagents to Aryl Azides.
22
23 *Tetrahedron Lett.* **1999**, *40* (47), 8305–8306.
24
25

26
27 (47) Cheng, K.; Kim, I. J.; Lee, M.-J.; Adah, S. A.; Raymond, T. J.; Bilsky, E. J.; Aceto, M.
28
29 D.; May, E. L.; Harris, L. S.; Coop, A.; Dersch, C. M.; Rothman, R. B.; Jacobson, A. E.; Rice, K.
30
31 C. Opioid Ligands with Mixed Properties from Substituted Enantiomeric N-Phenethyl-5-
32
33 Phenylmorphans. Synthesis of a M-Agonist Δ -Antagonist and Δ -Inverse Agonists. *Org. Biomol.*
34
35 *Chem.* **2007**, *5* (8), 1177–1190.
36
37

38
39 (48) Bogdal, D.; Matras, K.; Sanetra, J.; Pokladko, M. Synthesis of Polymethacrylates with
40
41 Carbazole and Benzofuran Pendant Groups for Photovoltaic Applications. *Macromol. Symp.*
42
43 **2008**, *268* (1), 48–52.
44
45

46
47 (49) Verbeek, J.; Syvänen, S.; Schuit, R. C.; Eriksson, J.; de Lange, E. C.; Windhorst, A. D.;
48
49 Luurtsema, G.; Lammertsma, A. A. Synthesis and Preclinical Evaluation of [11C]D617, a
50
51 Metabolite of (R)-[11C]verapamil. *Nucl. Med. Biol.* **2012**, *39* (4), 530–539.
52
53
54
55
56
57
58
59
60

1
2
3 (50) Behrens, C. H.; Chatterjee, D.; Hajra, A. K.; He, Y.; Li, H. Y.; Priestley, T.; Rudra, S.;
4 Saha, A. K.; Smith, R. A.; Thompson, S. K. Aminoindane Compounds and Use Thereof in
5 Treating Pain, WO2012112969 A1 August 23, 2012.
6
7

8
9
10
11 (51) Albani, D.; Arosio, R.; Merli, V. Process for Preparing N-Methyl-3, 4-
12 Dimethoxyphenylethylamine, US patent 20090171110 A1, July 2, 2009.
13
14

15
16
17 (52) Ramón-García, S.; Ng, C.; Anderson, H.; Chao, J. D.; Zheng, X.; Pfeifer, T.; Av-Gay, Y.;
18 Roberge, M.; Thompson, C. J. Synergistic Drug Combinations for Tuberculosis Therapy
19 Identified by a Novel High-Throughput Screen. *Antimicrob. Agents Chemother.* **2011**, *55* (8),
20 3861–3869.
21
22
23

24
25
26
27 (53) Rodrigues, L.; Machado, D.; Couto, I.; Amaral, L.; Viveiros, M. Contribution of Efflux
28 Activity to Isoniazid Resistance in the Mycobacterium Tuberculosis Complex. *Infect. Genet.*
29 *Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis.* **2012**, *12* (4), 695–700.
30
31
32

33
34
35 (54) Viveiros, M.; Rodrigues, L.; Martins, M.; Couto, I.; Spengler, G.; Martins, A.; Amaral, L.
36 Evaluation of Efflux Activity of Bacteria by a Semi-Automated Fluorometric System. *Methods*
37 *Mol. Biol. Clifton NJ* **2010**, *642*, 159–172.
38
39
40

41
42
43 (55) Rodrigues, L.; Ramos, J.; Couto, I.; Amaral, L.; Viveiros, M. Ethidium Bromide
44 Transport across Mycobacterium Smegmatis Cell-Wall: Correlation with Antibiotic Resistance.
45 *BMC Microbiol.* **2011**, *11* (1), 35.
46
47
48

49
50
51 (56) Viveiros M.; Martins, M.; Rodrigues, L.; Machado, D.; Couto, I.; Ainsa, J.; Amaral, L.
52 Inhibitors of Mycobacterial Efflux Pumps as Potential Boosters for Anti-Tubercular Drugs.
53 *Expert Rev Anti Infect Ther* **2012**, *10*, 983–998.
54
55
56
57
58
59
60

1
2
3 (57) Moody, J. A. 1992. Synergy testing: broth microdilution checkerboard and broth
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

macrodilution methods, in *Clinical microbiology procedures handbook*, ed H. D. Eisenberg, American Society for Microbiology, Washington, DC, 1992; pp. 5.18.1-5.18.23.

Figure 1. Structure of thioridazine and verapamil. In red the backbone that the two molecules share is shown.




Figure 2. Effect of thioridazine (TZ), verapamil (VP) and compound 10 on the accumulation (left) and efflux (right) of ethidium bromide (EtBr) at 0.5 $\mu\text{g/mL}$ by *M. tuberculosis* H37Rv. **Left panel:** *M. tuberculosis* H37Rv was loaded with 0.5 $\mu\text{g/mL}$ of EtBr with and without compounds. Verapamil (VP) and thioridazine (TZ) were tested at $\frac{1}{2}$ of their MIC whereas compound **10** was tested at 256 $\mu\text{g/mL}$, (see text for details). The increase in the fluorescence is directly proportional to the amount of EtBr that is retained within the cells. **Right panel:** *M. tuberculosis* H37Rv was loaded with 0.5 $\mu\text{g/mL}$ of EtBr in the presence of VP at $\frac{1}{2}$ of their MIC. Efflux of EtBr took place at 37 $^{\circ}\text{C}$ in the presence of glucose and was inhibited in the presence of the compounds at the same concentrations used on the accumulation assays (compare pink curve – no inhibitor – with the remaining curves – with inhibitor).




Figure 3. Fractional inhibitory concentration (FIC) determination for each combination against *M. tuberculosis* H37Rv. The effect of each compound on the activity of each antibiotic was represented by means of fractional inhibitory concentration (FIC) calculated as follows: $FIC = MIC_{\text{antibacterial in combination}} / MIC_{\text{antibacterial alone}}$. The FIC values were interpreted based on the criteria established as follows: $FIC \leq 0.25$, synergism; $0.25 > FIC < 2$, indifference and $FIC \geq 2$, antagonism.²⁴ The FIC value for the combinations was classified as ND (non-determinable) when the MICs of the compounds were greater than the highest, less than, or equal to the lowest concentration tested (Moody, 1992).⁵⁷ As such, FIC values were calculated at the following concentrations of the compounds: **7**, **10** and **11**, 128 $\mu\text{g/mL}$; **9**, 32 $\mu\text{g/mL}$; VP, 64 $\mu\text{g/mL}$, and TZ, 3.75 $\mu\text{g/mL}$ (see Table 3 for further information).







Figure 4. Determination of the intracellular activity of compounds **7**, **9**, **10** and **11** against *M. tuberculosis*-infected human macrophages. For the evaluation of the intracellular synergistic activity against *M. tuberculosis*-infected human monocyte-derived macrophages, INH and RIF were used at $\frac{1}{2}$ of its MIC (0.05 and 0.5 $\mu\text{g/mL}$, respectively). Macrophage viability was determined after 3 days of treatment with the compounds and for the subsequent intracellular assays, these were used at concentrations that were shown to be non-toxic for the macrophages: compound **7**, 16 $\mu\text{g/mL}$, **9**, 0.078 $\mu\text{g/mL}$; **10**, 1.25 $\mu\text{g/mL}$, and **11**, 40 $\mu\text{g/mL}$. Above these concentrations macrophage viability is reduced below 90%. The results are presented as a mean of the percentage of the survival \pm SD. (Figure S2)




Scheme 1.^{a,b} Preparation of the thioridazine analogues.

^aReagents and conditions: a) Ammonium acetate, toluene, α -benzyl-ethylacetoacetate, 150 °C, 1.5 h, 40%; b) 1-aminoadamantane, EDC·HCl, HOBT, triethylamine, DMF, rt, 24h, 49%; c) Isopropyl iodide, triethylamine, MeOH, reflux, 18h, 50%; d) Isopropyl bromide, NaH, DMF, rt, 18h, 47%; e) RNH, NaH, DMF, reflux, 18-72h, 9-70%; f) NaNH₂, Toluene, μ W, 110 °C, 30 min, 50%. ^bFor complete structures see chart 1.

Scheme 2.^a Preparation of the carbazole derivatives.

^aReagents and conditions: a) Dichloroethane, KOH, K₂CO₃, TBAF, 60 °C, 18h, 40%; b) piperidine, K₂CO₃, DMF, 60°C, 24h, 44%; c) *p*-Toluenesulfonyl chloride, triethylamine, DCM, rt, 18h, 75%; d) NaH, DMF, rt, 24h, 4%.

Chart 1. Structures of compounds 5-15^a

^aall compounds are mixture of enantiomers; ^bmixture of the diastereomers *Indicates the point of attachment

Table 1. Screening of the antimycobacterial and efflux inhibitory activity of the compounds against *M. smegmatis* mc2 155 and their toxicity assessed by the index of cytotoxicity (IC) towards human monocyte derived macrophages.

comp	<i>M. smegmatis</i> mc ² 155		IC ₅₀ ^c μg/mL(μM)
	MIC (μg/mL) ^a	RFF ± SD ^b	
5	>64 ^d	0.66 ± 0.13*	nd ^e
6	>256 ^d	0.17 ± 0.14	nd
7	>256 ^d	1.17 ± 0.46*	84.8 (264.7)
8	>256 ^d	0.72 ± 0.19*	nd
9	256	0.95 ± 0.15*	8.8 (30)
10	64	0.81 ± 0.27*	10.5 (32.51)
11	>256 ^d	15.34 ± 0.82***	170.8 (701.8)
12	64	0.94 ± 0.079**	0.762 (2.37)
13	>64 ^d	0.61 ± 0.16*	nd
14	256	0.76 ± 0.04**	nd
15	>256 ^d	0.39 ± 0.16*	nd
18	>64	-0.17 ± 0.16	nd
19	>256 ^d	0.08 ± 0.18	nd
TZ	30	0.82 ± 0.1*	5.6 (13.78)
VP	800	2.21 ± 0.14**	50.5 (116.6)

^a Determined by microdilution; ^b Relative final fluorescence based on accumulation of EtBr at 0.25 μg/mL; the results are presented as the average of three independent assays plus standard deviation (± SD). The results were considered significant when *P<0.05 and highly significant when **P<0.01 and ***P<0.001; ^c Index of Cytotoxicity (IC) determined in human monocyte derived macrophages; ^d Due to the reduced solubility of the compounds it was not possible to test at higher concentrations; ^e not determined.

Table 2. Evaluation of the antimycobacterial and efflux inhibitory activity of the selected compounds against *M. tuberculosis* H37Rv.

comp	<i>M. tuberculosis</i> H37Rv	
	MIC ($\mu\text{g/mL}$) ^a	RFF \pm SD ^b
7	>256 ^c	0.84 \pm 0.02*
9	128	0.33 \pm 0.11
10	>256 ^c	1.22 \pm 0.09*
11	>256 ^c	1.00 \pm 0.19
TZ	15	0.27 \pm 0.02
VP	512	1.94 \pm 0.005**

^a Determined by microdilution; ^b Relative final fluorescence (RFF) based on accumulation of EtBr at 0.5 $\mu\text{g/mL}$; the results are presented as the average of three independent assays plus standard deviation (\pm SD). The results were considered significant when *P<0.05 and highly significant when **P<0.01; ^c Due to the reduced solubility of the compounds it was not possible to test at higher concentrations.

Table 3. Evaluation of the synergistic effect and determination of the modulation factor (MF) of the selected compounds with first- and second- line drugs against *M. tuberculosis* H37Rv.

comp	test conc ^a	MIC (μg/mL) against <i>M. tuberculosis</i> H37Rv (MF) ^g				
		INH ^b	RIF ^c	AMK ^d	OFX ^e	EtBr ^f
no comp		0.1	1	2	2	12.5
7	256	0.1	<0.0156(>↓64)	2	1	12.5
	128	0.1	0.25(↓4)	2	2	12.5
	64	0.1	0.25(↓4)	2	2	12.5
	32	0.1	0.25(↓4)	2	2	12.5
	16	0.1	0.25(↓4)	2	2	12.5
	8	0.1	0.25(↓4)	2	2	12.5
	4	0.1	0.25(↓4)	2	2	12.5
9	64	<0.00078 (↓>128)	<0.0156(>↓64)	<0.0156 (>↓128)	<0.0156(>↓128)	<0.195 (>↓64)
	32	0.05	0.0625 (↓16)	0.625 (↓4)	1	1.56 (↓4)
	16	0.1	0.5	1	1	6.25
	8	0.1	0.5	1	1	12.5
	4	0.1	1	1	1	12.5
	2	0.1	1	1	1	12.5
	1	0.1	1	1	1	12.5
10	256	<0.00078 (↓>128)	<0.0156(>↓64)	<0.0156 (>↓128)	<0.0156(>↓128)	<0.195 (>↓64)
	128	<0.0015 (>↓64)	<0.0156(>↓64)	<0.0156 (>↓128)	<0.0156(>↓128)	<0.195 (>↓64)
	64	0.05	<0.0156(>↓64)	>0.0156 (>↓128)	<0.0156(>↓128)	1.56 (↓8)
	32	0.1	0.0312(↓32)	1	1	6.25
	16	0.1	0.0625(↓16)	1	1	12.5
	8	0.1	0.25(↓4)	1	1	12.5
	4	0.1	0.5	1	1	12.5
11	256	<0.00078 (↓>128)	<0.0156(>↓64)	<0.0156 (>↓128)	<0.0156(>↓128)	<0.195 (>↓64)
	128	0.1	0.5	1	1	12.5
	64	0.1	0.5	1	1	12.5
	32	0.1	0.5	1	1	12.5
	16	0.1	0.5	1	1	12.5
	8	0.1	0.5	1	1	12.5
	4	0.1	0.5	1	1	12.5
TZ	7.5	<0.00078 (↓>128)	<0.0156(>↓64)	<0.0156 (>↓128)	<0.0156(>↓128)	<0.195 (>↓64)
	3.75	0.05	1	1	1	3.125 (↓4)
	1.88	0.1	1	1	1	6.25

	0.94	0.1	1	1	1	6.25
	0.47	0.1	1	1	1	6.25
	0.23	0.1	1	1	1	6.25
	0.12	0.1	1	1	1	6.25
	128	<0.00078 (↓>128)	<0.0156(>↓64)	<0.0156 (>↓128)	<0.0156(>↓128)	<0.195 (>↓64)
	64	0.05	0.25 (↓4)	1	1	3.125 (↓4)
	32	0.1	0.5	1	1	6.25
VP	16	0.1	0.5	1	1	6.25
	8	0.1	0.5	1	1	12.5
	4	0.1	1	1	1	12.5
	2	0.1	1	1	1	12.5

^a Concentration at which the compound was tested (in µg/mL); ^b Isoniazid; ^c Rifampin; ^d Amikacin; ^e Ofloxacin; ^f Ethidium bromide; TZ, thioridazine; VP, verapamil. ^g modulation factor.

The modulation factor (MF) was calculated with the following formula: $MF = \frac{MIC_{\text{antibiotic}}}{MIC_{\text{combination}}}$

The modulation factor reflects a reduction of the MIC values of a given antibiotic in the presence of an inhibitor and was considered significant when $MF \geq 4$ (≥four-fold reduction). All experiments were repeated at least three times.

Supporting Information Available: ¹H NMR, ¹³C NMR description of compounds **5**, **6**, **9-15**, **18**, the synthesis of compounds **1-4**, **16**, **17** and the biological methods used for the determination of the MIC, the RFF and the synergistic activity are reported in the supporting information. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Author information

Corresponding authors:

Marco Pieroni, marco.pieroni@unipr.it, +39 0521905054

Miguel Viveiros, mveiros@ihmt.unl.pt, +351 213652653

Author Contributions

1
2
3 The manuscript was written through contributions of all authors. All authors have given approval
4 to the final version of the manuscript. # These authors contributed equally.
5
6
7


8 9 **Acknowledgments**

10
11 Giovanni Guerreschi is kindly acknowledged for the help in the synthesis of derivatives. This
12 work was partially supported by project PTDC/BIA-MIC/121859/2010 from Fundação para a
13 Ciência e a Tecnologia (FCT), Portugal. Diana Machado and Sofia Santos Costa were supported
14 by grants PTDC/BIA-MIC/121859/2010 (BI) and SFRH/BPD/97508/2013, respectively, from
15 FCT, Portugal.
16
17
18
19
20
21
22
23

24 **Abbreviations**

25
26 AMK, amikacin; DMF, *N,N*-dimethyl formamide; DOTS, directly observed therapy short-
27 course; EI, efflux inhibitor; INH, isoniazid; MIC, minimum inhibitory concentration; MDR-TB,
28 multidrug-resistant tuberculosis; *Mtb*, *Mycobacterium tuberculosis*; RIF, rifampicin; TB,
29 tuberculosis; TEA, triethylamine ; XDR-TB, extensively drug-resistant tuberculosis.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Table of Contents graphic



Thioridazine



Verapamil

Hybrid structure
inhibitor of efflux
7